| CD109 | 8A3, E123, Platelet activation factor |
| Molecule Type | Antigen Expression | Molecular Weight Min / Max |
| Non-lineage Restricted Molecule GPI anchor | Uterus Platelet Endothelium Tumor Cell Myeloid Leukemia Heart Lung Placenta Kidney Spleen T Cell Aorta Trachea Megakaryoblastic Cell Epithelial Cell | 170 / 170 |
Expression | ||||||||||||||
| CD109 is expressed on activated T cells, platelets, human umbilical vein endothelial cells, acute myeloid leukemia cell lines and several tumor cell lines but it is not expressed on resting lymphocytes, neutrophils and erythrocytes. Expression is on chronic myeloid leukemia. There is a wide level of expression in uterus, aorta, heart, lung, trachea, placenta and in fetal heart, kidney, liver and spleen. | ||||||||||||||
Structure | ||||||||||||||
| MOLECULAR FAMILY NAME: Belongs to the α2 microglobulin family of thioester-containing proteins. CD109 is a GPI-anchored glycoprotein. It contains a 21 aa N-terminal sequence and an extracellular domain which contains 17 potential N-linked carbohydrate glycosylation sites, a GPI-anchor site and a thioester motif characteristic of the α-2-macroglobulin. About 50% of the antigen can be released from platelets by phosphatidylinositol-specific phospholipase C. Multiple chains are observed by immunoprecipitation but the lower bands are proteolytic products of a single chain. There are 2 N-linked sites that have been found by peptide mapping. No change in polypeptide chain size is observed with O-glycanase. MOLECULAR MASS
POST-TRANSCRIPTIONAL MODIFICATION Alternative splicing yields 4 different isoforms. POST-TRANSLATIONAL MODIFICATION: No information. | ||||||||||||||
Ligands | ||||||||||||||
| LIGANDS AND MOLECULES ASSOCIATED WITH CD109: No information. | ||||||||||||||
Function | ||||||||||||||
| CD109 carries the epitopes for the Gov a/b alloantigen on platelets. CD109 is a research reagent for the study of progenitor cell subsets. BIOCHEMICAL ACTIVITY: No information. DISEASE RELEVANCE AND FUNCTION OF CD109 IN INTACT ANIMAL Alloantibodies against CD109 have been identified in patients following multiple platelet transfusions. The alloantigenicity of CD109 has been implicated in post-transfusion purpura and alloimmune neonatal thrombocytopenia. | ||||||||||||||
Comments | ||||||||||||||
| MOLECULAR INTERACTIONS- PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD109: No information. SUBSTRATE: No information. ENZYMES WHICH MODIFY CD109: No information. | ||||||||||||||
Database accession numbers | ||||||||||||||
Revised June 25, 2008
|
||||||||||||||